N/A N=9 FES Rowing for Skeletal Health After SCI
Spinal Cord Injury
Primary: Bone Mineral Density — 184.0; 174.9; 188.5 g/cm^3
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=36 Pharmacokinetics of Lanraplenib in Adults With Impaired Renal Function
Inflammatory Disease
Primary: Pharmacokinetic (PK) Parameter: AUClast of Lanraplenib Presented Based on Range of CLcr — 2317.8; 2027.4; 2076.3; 1871.6 h*ng/mL
N/A N=9 Computed Tomography for Evaluating Supination-external Rotation Type Ankle Fractures
Supination-external Rotation Ankle Fractures
Primary: Medial Clear Space Distance in the Ankle Joint — 1.41 mm
N/A N=50 Feasibility and Acceptability of a Beverage Intervention for Hispanic Adults
Obesity · Hypercholesterolemia · Hyperglycemia
Primary: Study Recruitment: Interest in Participation — 279 Participants
N/A N=41 Pilot Study for a Prospective Surveillance Program for Rehabilitation Following Surgery for Breast Cancer
Breast Cancer
Primary: Number of Participants With Arm Morbidity at 12 Months Post-surgery - Shoulder Mobility — 5; 7 Participants
N/A N=16 Inspiratory Muscle Training and Asthma
Asthma
Primary: Maximal Inspiratory Mouth Pressure (MIP) — 9.36; 9.37; 10.55; 9.21 kPa
N/A N=3,125 Nonsmokers Helping Smokers Quit
Smoking Cessation
Primary: Number of Participants Reporting 30-day Abstinence — 203; 222; 135 Participants
Phase 1 N=27 Acute Exercise Cardioprotection From Doxorubicin
Breast Cancer
Primary: Global Longitudinal Strain — 19.2; -19.6; 21.4; -21.5 % deformation
Phase 3 N=1,384 EC Followed Docetaxel Versus ET Followed Capecitabine as Adjuvant Chemotherapy for Node Positive Operable Breast Cancer
Breast Cancer
Primary: Number of Participants With Disease-free Survival (DFS) Event — 127; 170 Participants
Phase 2 N=213 Study of the Efficacy and Safety of MEDI4893
Staphylococcus Aureus Pneumonia
Primary: Percentage of Participants With Endpoint Adjudication Committee-Determined (EAC) Staphylococcus Aureus (S Aureus) Pneumonia — 26.0; 20.0; 17.7 Percentage of Participants…
N/A N=108 A Study to Assess the Safety and Efficacy of Enantone (Leuprorelin) in Central Precocious Puberty (CPP) Among Chinese Participants
Central Precocious Puberty
Primary: Number of Participants With at Least One Treatment Emergent Adverse Event (TEAE) and Serious Adverse Event (SAE) During Enantone Treatment Phase — 4; 71; 0; 2 Participants
N/A N=74 The Effectiveness of a Physiotherapy Technique in Patients With Chronic Myofascial Temporomandibular Disorder
Myofascial Pain Syndrome · Temporomandibular Disorder
Primary: Changes of Perceived Pain Between Three Time Points (Baseline, Post-treatment, and 3 Months Later) and Between Groups (Sham Simulation and Pressure Release Technique)…
N/A N=130 A Comparative Study of Different Treadmill Scores to Diagnose Coronary Artery Disease
Stable Ischemic Heart Disease
Primary: Exercise Treadmill Scores — 0.771; 0.772; 0.768 Probability by AUC
Phase 1 N=60 Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Neoadjuvant Treatment for Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-173/KEYNOTE-173)
Triple Negative Breast Neoplasms
Primary: Number of Participants With Dose Limiting Toxicities (DLTs) Graded Using National Cancer Institute Common Toxicity Criteria for Adverse Events Version 4.0 (NCI CTCAE…
Phase 2 N=130 Study to Evaluate Exemestane With and Without Entinostat (SNDX-275) in Treatment of Postmenopausal Women With Advanced Breast Cancer
Breast Cancer · Estrogen Receptor-Positive Breast Cancer · Breast Cancer, Estrogen Receptor-Positive
Primary: Progression-free Survival (PFS) — 2.27; 4.28 months — p=0.06